Insider activity (SEC Form 4)
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
Open-market · last 30 days:
2 buyers bought $157K
1 seller sold $239K
Open-market · last 90 days:
2 buyers bought $157K
1 seller sold $239K
| Insider | Role | Date | Transaction | Shares | Value |
|---|
| Bowen Julie Marie |
Director |
2026-07-14 |
Grant/award |
2874 |
$13K |
| Daly Joseph Patrick |
Director, 10% Owner |
2026-07-14 |
Grant/award |
2874 |
$13K |
| Daly Joseph Patrick |
Director, 10% Owner |
2026-07-14 |
Open-market buy |
2126 |
$10K |
| Loh Michael Anthony |
Director |
2026-07-14 |
Grant/award |
2874 |
$13K |
| Yowell Jeffrey David |
Director |
2026-07-14 |
Grant/award |
2874 |
$13K |
| Zeff Capital, LP |
10% Owner |
2026-07-14 |
Open-market sell |
36925 |
$172K |
| Daly Joseph Patrick |
Director, 10% Owner |
2026-07-13 |
Open-market buy |
7500 |
$33K |
| Daly Joseph Patrick |
Director, 10% Owner |
2026-07-13 |
Open-market buy |
2500 |
$11K |
| Zeff Capital, LP |
10% Owner |
2026-07-13 |
Open-market sell |
11050 |
$49K |
| Daly Joseph Patrick |
Director, 10% Owner |
2026-07-10 |
Open-market buy |
5000 |
$22K |
| Daly Joseph Patrick |
Director, 10% Owner |
2026-07-10 |
Open-market buy |
6000 |
$26K |
| Daly Joseph Patrick |
Director, 10% Owner |
2026-07-10 |
Open-market buy |
7000 |
$30K |
| Daly Joseph Patrick |
Director, 10% Owner |
2026-07-10 |
Open-market buy |
2000 |
$9K |
| Loh Michael Anthony |
Director |
2026-07-10 |
Open-market buy |
3658 |
$16K |
| Zeff Capital, LP |
10% Owner |
2026-07-10 |
Open-market sell |
4000 |
$18K |
| Sefchick Adam Brett |
Chief Financial Officer |
2026-05-01 |
Tax withholding |
5645 |
$23K |
| Daly Joseph Patrick |
Director, 10% Owner |
2026-03-20 |
Open-market buy |
1000 |
$4K |
| Daly Joseph Patrick |
Director, 10% Owner |
2026-03-19 |
Open-market buy |
745 |
$3K |
| Bowen Julie Marie |
Director |
2026-03-17 |
Grant/award |
3255 |
$12K |
| Daly Joseph Patrick |
Director, 10% Owner |
2026-03-17 |
Grant/award |
3255 |
$12K |
Most recent 20 reported transactions. Open-market buys (P) and sells (S) are the deliberate ones; grants and option exercises are compensation. Not investment advice.
8-K
filed 2026-07-08
confidence 98%
Item 2.02
Butler National Corporation issued a press release on July 8, 2026 announcing financial results for the fiscal year ended April 30, 2026, disclosing significant performance metrics: revenue increased 17% to $98.0 million, operating income increased 69% to $28.5 million, net income increased 75% to $21.9 million, and earnings per share increased to $0.34 from $0.19. The press release is attached as Exhibit 99 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. These material financial results would affect a reasonable investor's assessment of the registrant's performance and financial condition.
View raw filing on EDGAR →
8-K
filed 2026-06-15
confidence 85%
Item 5.02
Adam B. Sefchick was appointed as Interim Chief Executive Officer and President effective June 15, 2026, following the immediate retirement of Christopher J. Reedy as CEO. The appointment addresses continuity of executive leadership.
View raw filing on EDGAR →
8-K
filed 2026-06-10
confidence 92%
Item 8.01
The Compensation Committee approved a $90,000 cash increase in annual compensation for Jeffrey D. Yowell, the Executive Chairman, effective June 1, 2026, bringing his total annual compensation to $340,000. This is a direct disclosure of a compensatory arrangement modification for a named executive officer, which falls squarely within the exec_compensation category. The materiality is supported by the magnitude of the increase and the fact that it was formally approved by the Committee.
View raw filing on EDGAR →
8-K
filed 2026-06-01
confidence 72%
Item 8.01
The disclosure reveals that CEO Christopher J. Reedy is undergoing medical treatment at Mayo Clinic, which could materially affect investor assessment of leadership continuity and operational risk. While the company emphasizes his continued active engagement and the strength of the leadership team, the fact that treatment may "periodically require time away from the office" and the Board's explicit statements of support suggest a material health-related concern about the CEO. This does not fit neatly into exec_departure (he remains CEO) or exec_appointment, but the medical situation and its potential operational implications warrant material disclosure under Item 8.01.
View raw filing on EDGAR →